Haemonetics Corporation $HAE Shares Acquired by M&T Bank Corp

M&T Bank Corp grew its position in Haemonetics Corporation (NYSE:HAE) by 205.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,370 shares of the medical instruments supplier’s stock after purchasing an additional 9,673 shares during the period. M&T Bank Corp’s holdings in Haemonetics were worth $1,050,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the company. AQR Capital Management LLC lifted its stake in shares of Haemonetics by 372.8% in the 3rd quarter. AQR Capital Management LLC now owns 2,128,878 shares of the medical instruments supplier’s stock valued at $102,814,000 after purchasing an additional 1,678,630 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Haemonetics by 2.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,099,519 shares of the medical instruments supplier’s stock valued at $53,587,000 after purchasing an additional 26,763 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Haemonetics by 11.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,060,790 shares of the medical instruments supplier’s stock valued at $51,777,000 after purchasing an additional 111,307 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Haemonetics by 4,296.3% in the 3rd quarter. Millennium Management LLC now owns 773,179 shares of the medical instruments supplier’s stock valued at $37,685,000 after purchasing an additional 755,592 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH lifted its stake in shares of Haemonetics by 1.5% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 716,997 shares of the medical instruments supplier’s stock valued at $57,467,000 after purchasing an additional 10,685 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Trading Up 1.8%

Shares of HAE stock opened at $60.05 on Friday. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.15 and a current ratio of 1.75. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32. The stock has a fifty day moving average of $59.96 and a two-hundred day moving average of $66.35. The firm has a market capitalization of $2.79 billion, a PE ratio of 16.54, a price-to-earnings-growth ratio of 1.16 and a beta of 0.36.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The company had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. During the same quarter in the previous year, the firm posted $1.19 EPS. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. As a group, research analysts expect that Haemonetics Corporation will post 4.95 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on HAE shares. Robert W. Baird set a $81.00 price objective on Haemonetics in a research note on Friday, February 6th. Citigroup reduced their price objective on Haemonetics from $75.00 to $70.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 11th. Mizuho reduced their price objective on Haemonetics from $80.00 to $70.00 and set an “outperform” rating on the stock in a research note on Monday, April 13th. Barrington Research set a $94.00 price target on Haemonetics in a research report on Friday, February 6th. Finally, Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, Haemonetics presently has a consensus rating of “Moderate Buy” and a consensus price target of $82.78.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.